Sattva Neelapu

Sattva Neelapu is a pioneer in CD19-directed CAR-T cell therapy for aggressive B cell lymphoma, having led ZUMA-1 — the pivotal trial that resulted in the first FDA approval of axicabtagene ciloleucel (axi-cel) for relapsed/refractory DLBCL in 2017. He subsequently led ZUMA-7 establishing axi-cel as the preferred second-line therapy in early relapsed DLBCL. His laboratory investigates CAR-T cell manufacturing, T cell fitness, mechanisms of CAR-T failure, and the pathophysiology and management of CAR-T toxicities including ICANS.